Jim Cramer suggests waiting for a further GEHC downgrade before buying more shares. Avity Investment Management Inc. is expanding their stake in GEHC. Q3 2024 results are expected to be released on October 30, 2024. Various companies like Sanctuary Advisors LLC and True North Advisors LLC are increasing their shares in GEHC. GEHC is advancing enterprise imaging by accelerating artificial intelligence adoption. Results from Phase I of a macrocyclic manganese-based MRI contrast agent trial have been announced. Juicing up their AI efficiency, GEHC has acquired Intelligent Ultrasound's clinical AI business. They also commenced a secondary offering of 10,000,000 shares. GEHC shows a promising future with 75% institutional-owned shares, and is expected to profit from AI algorithms. Despite former parent selling off half its stake, stock rose after AI-powered Venue Sprint's launch. The company was raised to a buy at BTIG on potential H2 beat. GEHC stock is expected to rise after FDA approved Flyrcado. Encouraging long-term growth prospects are expected, despite insider selling. Lastly, their stock dropped after downgraded guidance, possibly due to a Q1 shortfall and miss in Q2 earnings.
Ge Healthcare Technologies GEHC News Analytics from Tue, 13 Feb 2024 08:00:00 GMT to Sat, 12 Oct 2024 14:07:24 GMT -
